Personalis, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Personalis, Inc. | PSNL - NASDAQ |
$14.00-$16.00 | $17.00 | $23.70 | 7.92 million | 6/20/2019 |
| Morgan Stanley, BofA Merrill Lynch, Cowen | ||||||
Co-Manager(s): Oppenheimer & Co. | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-05-23 Terms Added 2019-06-07 | ||||||
Personalis, Inc. Quote & Chart - Click for current quote - PSNL
IPO Boutique aggregates information on public companies and private companies, such as "PSNL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Personalis, Inc. (adapted from Personalis, Inc. prospectus):
They are a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PSNL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.